Optimal Management of Neutropenic Fever in Patients With Cancer

Andrea J. Zimmer, Alison Gail Freifeld

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Febrile neutropenia remains an important complication of treatment with cytotoxic chemotherapy. It is often the first and sometimes the only sign or symptom of infection in this vulnerable patient population. Urgent and appropriate evaluation and treatment are imperative because delay in initiating appropriate antibiotic therapy may be life threatening. Selection of antibiotics should be based on the patient's symptoms, previous culture data, and institutional antibiograms. Ongoing therapy should be guided by culture and clinical data. Antimicrobial resistance is of great concern, particularly in this population, so careful attention to antibiotic selection and duration is needed.

Original languageEnglish (US)
Pages (from-to)19-24
Number of pages6
JournalJournal of Oncology Practice
Volume15
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Fever
Anti-Bacterial Agents
Neoplasms
Febrile Neutropenia
Microbial Sensitivity Tests
Vulnerable Populations
Therapeutics
Signs and Symptoms
Drug Therapy
Infection
Population

ASJC Scopus subject areas

  • Oncology
  • Oncology(nursing)
  • Health Policy

Cite this

Optimal Management of Neutropenic Fever in Patients With Cancer. / Zimmer, Andrea J.; Freifeld, Alison Gail.

In: Journal of Oncology Practice, Vol. 15, No. 1, 01.01.2019, p. 19-24.

Research output: Contribution to journalArticle

@article{6e48c3f43f0d48a2a81c57b2244b90f3,
title = "Optimal Management of Neutropenic Fever in Patients With Cancer",
abstract = "Febrile neutropenia remains an important complication of treatment with cytotoxic chemotherapy. It is often the first and sometimes the only sign or symptom of infection in this vulnerable patient population. Urgent and appropriate evaluation and treatment are imperative because delay in initiating appropriate antibiotic therapy may be life threatening. Selection of antibiotics should be based on the patient's symptoms, previous culture data, and institutional antibiograms. Ongoing therapy should be guided by culture and clinical data. Antimicrobial resistance is of great concern, particularly in this population, so careful attention to antibiotic selection and duration is needed.",
author = "Zimmer, {Andrea J.} and Freifeld, {Alison Gail}",
year = "2019",
month = "1",
day = "1",
doi = "10.1200/JOP.18.00269",
language = "English (US)",
volume = "15",
pages = "19--24",
journal = "Journal of Oncology Practice",
issn = "1554-7477",
publisher = "American Society of Clinical Oncology",
number = "1",

}

TY - JOUR

T1 - Optimal Management of Neutropenic Fever in Patients With Cancer

AU - Zimmer, Andrea J.

AU - Freifeld, Alison Gail

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Febrile neutropenia remains an important complication of treatment with cytotoxic chemotherapy. It is often the first and sometimes the only sign or symptom of infection in this vulnerable patient population. Urgent and appropriate evaluation and treatment are imperative because delay in initiating appropriate antibiotic therapy may be life threatening. Selection of antibiotics should be based on the patient's symptoms, previous culture data, and institutional antibiograms. Ongoing therapy should be guided by culture and clinical data. Antimicrobial resistance is of great concern, particularly in this population, so careful attention to antibiotic selection and duration is needed.

AB - Febrile neutropenia remains an important complication of treatment with cytotoxic chemotherapy. It is often the first and sometimes the only sign or symptom of infection in this vulnerable patient population. Urgent and appropriate evaluation and treatment are imperative because delay in initiating appropriate antibiotic therapy may be life threatening. Selection of antibiotics should be based on the patient's symptoms, previous culture data, and institutional antibiograms. Ongoing therapy should be guided by culture and clinical data. Antimicrobial resistance is of great concern, particularly in this population, so careful attention to antibiotic selection and duration is needed.

UR - http://www.scopus.com/inward/record.url?scp=85059829136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059829136&partnerID=8YFLogxK

U2 - 10.1200/JOP.18.00269

DO - 10.1200/JOP.18.00269

M3 - Article

VL - 15

SP - 19

EP - 24

JO - Journal of Oncology Practice

JF - Journal of Oncology Practice

SN - 1554-7477

IS - 1

ER -